Session » Rheumatoid Arthritis – Etiology and Pathogenesis Poster II

Date: Monday, October 22, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1065

Artesunate Can Synergize with Methotrexate on Inhibiting Migration and Invasion of Fibroblast-like Synoviocytes from Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1056

Association of Paraoxonase 1 Gene Polymorphisms and Enzyme Activity with Progression of Carotid Atherosclerosis in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1075

Automated Multiparameter Microscopy and Image Analysis: Next Generation Synovial Tissue Histology

9:00AM-11:00AM: Abstract Number: 1057

Autophagy Promotes Citrullination of Vimentin and Its Interaction with Major Histocompatibility Complex Class II in Synovial Fibroblasts

9:00AM-11:00AM: Abstract Number: 1068

Characterization of the Role of Endocannabinoid System Using Jwh-133, a Selective Cannabinoid CB2 Receptor Agonist, in IL-1β-Induced Inflammation in Human Rheumatoid Arthritis Synovial Fibroblasts

9:00AM-11:00AM: Abstract Number: 1073

Connective Tissue Growth Factor Associates with Angiogenesis through Notch-1 Activation in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1059

Differentially-Utilized Transcription Factors and Enhancers in Rheumatoid Arthritis (RA) Fibroblast-like Synoviocytes

9:00AM-11:00AM: Abstract Number: 1074

Distinct Metabolic Profile in the Urine of Rheumatoid Arthritis Patients:a Possible Link to Arthritis Phenotypes

9:00AM-11:00AM: Abstract Number: 1058

Doxycycline Directly Scavenges Reactive Oxygen Species and Inhibits the Formation of Malondialdehyde-Acetaldehyde-Protein Adducts – a Novel Mechanism of Action for an Old Drug

9:00AM-11:00AM: Abstract Number: 1072

Fibrin-Triggered Chondrosynovial Adhesion As a Novel Mechanism of Cartilage Damage in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1064

Identification of a Panel of Circulating Proteins Associated to Synovial Pathotypes in Early Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 1077

Identification of Biomarkers Involved in the Resolution Phase of Inflammation: Specialized Pro-Resolving Mediator Receptors Expression in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1062

Linking Systemic Angiogenic Markers to Synovial Vascularization in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1069

Non-Receptor Protein Tyrosine Phosphatase 14 (PTPN14) Promotes YAP-Dependent Tgfbeta Signaling in RA FLS

9:00AM-11:00AM: Abstract Number: 1076

Phospholipase C-eta2, As a C2 Domain-Containing Protein, Regulate Aggressiveness of Fibroblast‐like Synoviocytes and Ameliorate Arthritis in Experimental Animal Models of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1071

Protective Role of the Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Rs2495477 Polymorphism in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1063

Role of Mitochondrial-Bound HK2 in Rheumatoid Arthritis Fibroblast-like Synoviocytes

9:00AM-11:00AM: Abstract Number: 1070

Seroreactivity Against Recombinant Citrullinated Myosin Is Associated with Measures of Diastolic Dysfunction in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1061

Serum Metabolomic Profiling Predicts Synovial Gene Expression in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1067

Simulating the Pathogenesis of Arthritis in Vitro By Developing a Human-Based Multicomponent 3D Joint Model

9:00AM-11:00AM: Abstract Number: 1078

Standardization of Synovial Biopsies Procedures across Centers: A Consensus Initiative Using a Delphi Survey

9:00AM-11:00AM: Abstract Number: 1066

Tocilizumab Effect on Serum Angiogenic Factors in Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 1060

Variation in the Synovial Fluid Metabolome According to Disease Activity in Rheumatoid Arthritis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].